The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
Location status: Recruiting
NCT Number: NCT07331987
This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants receive Probiotic product once daily by oral, 60B CFU/day for 3 months.
Participants receive Placebo once daily by oral for 3 months.
Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg/day for 3 months.
Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)
Depression symptoms will be assessed using the 24-item Hamilton Depression Rating Scale (HAM-D-24) at baseline and the specified time points during the study. With higher scores indicating more severe depression, and scores categorized as <8 non-depressed, 8-19 mild, 20-34 moderate, ≥35 severe for diagnosis and monitoring treatment response.
Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)
Anxiety symptoms will be evaluated using 14-item Hamilton Anxiety Rating Scales (HAM-A) at baseline and the specified time point during the study. Each item is scored on a scale of 0 (not present) to 4 (severe). The total score, calculated by summing all items, ranges from 0 to 56, with higher scores indicating greater anxiety severity, where 0-7 indicates no/minimal, 8-14 mild, 15-23 moderate and ≥24 severe.
Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)
Assesses sleep quality from baseline to end of the study by questionnaire of The Pittsburgh Sleep Quality Index (PSQI). There are 19 items that are used to generate 7 component scores, which then are added together to determine a global score that ranges between 0 to 21, where higher scores reflect worse sleep quality.
Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)
Assessment of gastrointestinal symptoms will conducted at baseline and throughout the study period. The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.
Contact information is provided by the study sponsor or research team.
Moon (Guangzhou) Biotechnology Co., Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Efficacy and Safety of Probiotics in Participants With Anxiety Depression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07653035
Anxiety Depression, Anxiety Disorders
Muscat, Seeb, Oman
View Trial DetailsNCT07143539
Anxiety Depression, Anxiety Disorders
Aarau, Switzerland
View Trial DetailsNCT05658796
Anxiety, Anxiety Depression
Monroeville, Pennsylvania, United States
View Trial DetailsNCT07617467
Anxiety, Anxiety Depression
Arendal, Agder, Norway
View Trial Details